Currently, BC classification and therapy assessment are mainly based on tumor staging/grading and the following molecular biomarkers: estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2) and Ki-67 (proliferation marker). Here, MKI67 is linked to breast cancer.